Your browser doesn't support javascript.
loading
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Earl, Helena M; Hiller, Louise; Dunn, Janet A; Blenkinsop, Clare; Grybowicz, Louise; Vallier, Anne-Laure; Abraham, Jean; Thomas, Jeremy; Provenzano, Elena; Hughes-Davies, Luke; Gounaris, Ioannis; McAdam, Karen; Chan, Stephen; Ahmad, Rizvana; Hickish, Tamas; Houston, Stephen; Rea, Daniel; Bartlett, John; Caldas, Carlos; Cameron, David A; Hayward, Larry.
Affiliation
  • Earl HM; University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, and Cambridge Breast Cancer Research Unit Cambridge, Cambridge, UK. Electronic address: hme22@cam.ac.uk.
  • Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Blenkinsop C; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Grybowicz L; Cambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, UK.
  • Vallier AL; Cambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, UK.
  • Abraham J; University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, and Cambridge Breast Cancer Research Unit Cambridge, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Thomas J; Western General Hospital, Edinburgh, UK.
  • Provenzano E; NIHR Cambridge Biomedical Research Centre, and Cambridge Breast Cancer Research Unit Cambridge, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Hughes-Davies L; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Gounaris I; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • McAdam K; Peterborough City Hospital, Edith Cavell Campus, Peterborough, UK.
  • Chan S; Nottingham University Hospital (City Campus), Nottingham, UK.
  • Ahmad R; West Middlesex University Hospital, Isleworth, UK.
  • Hickish T; Royal Bournemouth Hospital, Bournemouth University, Bournemouth, UK.
  • Houston S; The Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK.
  • Rea D; City Hospital, Dudley Road, Birmingham, UK.
  • Bartlett J; Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK.
  • Caldas C; University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK; NIHR Cambridge Biomedical Research Centre, and Cambridge Breast Cancer Research Unit Cambridge, Cambridge, UK; Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Cameron DA; Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK.
  • Hayward L; Western General Hospital, Edinburgh, UK.
Lancet Oncol ; 16(6): 656-66, 2015 Jun.
Article in En | MEDLINE | ID: mdl-25975632
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Taxoids / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Taxoids / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article